



RECEIVED

APR 22 2002

PATENT APPLICATION
Attorney Docket # 1600/2900
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

TAKENOUCHI, KAZUYA, et al.

Appln. No.: 10/035,251

Group Art Unit: 1616

Confirmation No.: 4355

Examiner: Not yet Assigned

Filed: January 04, 2002

For: VITAMIN D3 DERIVATIVE AND TREATING AGENT FOR INFLAMMATORY
RESPIRATORY DISEASE USING SAME

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231


Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following correction(s):

Title: Vitamin D3 [dervative] derivative and treating agent for inflammatory respiratory disease using the same

Verification for the requested corrections is indicated on the original Declaration and power of Attorney filed January 4, 2002.

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: April 15, 2002

RECEIVED

APR 22 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20503
 www.uspto.gov

| APPLICATION NUMBER | FILING DATE | GRP ART UNIT | FIL FEE REC'D | ATTY DOCKET NO | DRAWINGS | TOT CLAIMS | IND CLAIMS |
|--------------------|--------------|--------------|---------------|----------------|----------|------------|------------|
| ✓ 10/035,251 | ✓ 01/04/2002 | 1616 | ✓ 1074 | ✓ Q67009 | | ✓ 17 | 1 |

CONFIRMATION NO. 4355

FILING RECEIPT



OC000000007498313

 SUGHRUE MION, PLLC
 2100 Pennsylvania Avenue, NW
 Washington, DC 20037-3213

Date Mailed: 02/20/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

- ✓ Kazuya Takenouchi, Tokyo, JAPAN;
- ✓ Qingzhi Gao, Tokyo, JAPAN;
- ✓ Kenji Manabe, Tokyo, JAPAN;
- ✓ Ryo Sogawa, Tokyo, JAPAN;
- ✓ Yasuhiro Takano, Tokyo, JAPAN;
- ✓ Seiichi Ishizuka, Tokyo, JAPAN;

Assignment For Published Patent Application

TEIJIN LIMITED;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/830,167 04/23/2001

Foreign Applications

- ✓ JAPAN 10/302321 10/23/1998
- ✓ JAPAN 10/362827 12/21/1998
- ✓ JAPAN 10/365207 12/22/1998
- JAPAN 10/365208 12/22/1998
- JAPAN 10/365209 12/22/1998

If Required, Foreign Filing License Granted 02/19/2002


Projected Publication Date: 05/30/2002

Non-Publication Request: No

RECEIVED

APR 22 2002

TECH CENTER 1600/2900



Early Publication Request: No

Title

Vitamin D3 ^{derivative} and treating agent for inflammatory respiratory disease using same

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

* This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).